Both Pfizer and Moderna, two pharmaceutical companies tasked with providing a vaccine for COVID-19 have reported that their results are more than 90% effective.
Pfizer shared their news on November 18, saying that their vaccine had a success rate of 95% and that they were looking to clear it soon. As documented by the Seattle Times, Pfizer, along with their partner, BioNTech, are currently prepping to formally ask the U.S. if the vaccine can begin being used immediately.
Meanwhile, Moderna has completed studies in the UK and Brazil, and revealed that the vaccine was highly effective in preventing COVID-19.
“No hospitalizations or severe cases were reported in study participants. [We] will now immediately prepare regulatory submission of the data to authorities around the world that have a framework in place for conditional or early approval,” Moderna’s study noted. “The Company will seek an Emergency Use Listing from the World Health Organization for an accelerated pathway to vaccine availability in low-income countries.”
The groups that are first in line to receive the vaccine are health care workers, first responders and essential workers. If all goes as planned, with the Food and Drug Administration still needing to debate results, Pfizer’s vaccine could be rolled out as early as December.
—
ESSENCE is committed to bringing our audience the latest facts about COVID-19 (coronavirus). Our content team is closely monitoring the developing details surrounding the virus via official sources and health care experts, including the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC) and the Occupational Safety and Health Administration (OSHA). Please continue to refresh ESSENCE’s informational hub for updates on COVID-19, as well as for tips on taking care of yourselves, your families and your communities.